This therapeutic approach targets dysregulated calcium signaling in neurodegenerative diseases by modulating mitochondrial calcium uniporter (MCU) complexes, store-operated calcium entry (SOCE) channels, and plasma membrane calcium ATPase (PMCA) activity to restore neuronal calcium homeostasis and prevent excitotoxic cell death.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | MCU modulators and SOCE inhibitors are emerging targets; not yet in clinical trials for neurodegeneration |
| Mechanistic Rationale | 9 | Calcium dysregulation is a well-established early event in AD/PD; MCU inhibition prevents mitochondrial calcium overload; SOCE modulation restores ER calcium |
| Root-Cause Coverage | 8 | Addresses upstream calcium dysregulation that drives multiple downstream pathologies (excitotoxicity, mitochondrial dysfunction, ER stress) |
| Delivery Feasibility | 7 | Blood-brain barrier penetration achievable with small molecule inhibitors; brain-penetrant MCU inhibitors in development |
| Safety Plausibility | 7 | Tight therapeutic window but manageable with careful dosing; calcium essential but modulatable |
| Combinability | 9 | Synergizes with mitochondrial protectors (SIRT1/NAD+), autophagy inducers (TFEB), and anti-excitotoxic drugs (memantine) |
| Biomarker Availability | 8 | Calcium imaging biomarkers (Fura-2, GCaMP); mitochondrial calcium sensors (RCaMP); CSF calcium levels |
| De-risking Path | 8 | Can start with well-characterized compounds (e.g., MCU inhibitor Ru360) in rodent models; advance to brain-penetrant candidates |
| Multi-disease Potential | 9 | Strong rationale for AD, PD, ALS, HD, and aging-related neurodegeneration |
| Patient Impact | 8 | Addresses fundamental neuronal dysfunction; potential for disease modification rather than symptomatic relief |
Total Score: 79/100
Novel target (calcium homeostasis) — targets mitochondrial and ER calcium handling
| Disease | Coverage | Rationale |
|---|---|---|
| Alzheimer's Disease | 9 | Calcium dysregulation precedes amyloid; MCU inhibition reduces excitotoxicity; SOCE normalization improves synaptic function |
| Parkinson's Disease | 9 | Calcium dysregulation in dopaminergic neurons is well-documented; MCU modulators protect against MPTP/6-OHDA toxicity |
| Amyotrophic Lateral Sclerosis | 7 | Calcium dysregulation in motor neurons; MCU inhibition reduces excitotoxic cell death |
| Frontotemporal Dementia | 6 | Calcium handling defects in tauopathy models; moderate rationale |
| Aging | 9 | Calcium dysregulation is a hallmark of aging neurons; restoration improves cognitive function in aged models |
Calcium (Ca²⁺) is a critical second messenger in neurons, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cell survival. In neurodegenerative diseases, calcium homeostasis becomes dysregulated through multiple mechanisms:
Mitochondrial Calcium Overload: The mitochondrial calcium uniporter (MCU) allows excessive Ca²⁺ influx during neuronal activity, leading to mitochondrial depolarization, ROS generation, and permeability transition pore opening[1].
Store-Operated Calcium Entry (SOCE): Dysfunction of STIM1/Orai1 channels leads to abnormal Ca²⁺ influx and ER calcium depletion, triggering unfolded protein response (UPR)[2].
Plasma Membrane Dysregulation: Reduced PMCA and NCX activity impairs calcium extrusion, leading to intracellular accumulation[3].
Excitotoxicity: Excessive glutamate receptor activation (especially NMDA receptors) causes pathological Ca²⁺ influx, activating calpains and degenerative pathways[4].
MCU Modulation:
SOCE Inhibition:
Calcium Buffering Enhancement:
| Trial ID | Compound | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|---|---|---|---|---|---|---|
| NCT00040144 | Nimodipine | Phase 3 | 1,652 | AD | ADAS-Cog change | No significant cognitive benefit vs placebo (p=0.23) |
| NCT00232782 | Nimodipine | Phase 3 | 450 | VaD | CIBIC-plus | Modest benefit in vascular dementia (p=0.04) |
| NCT00145158 | Memantine + Donepezil | Phase 3 | 403 | AD | ADAS-Cog | Combined therapy improved cognition (p=0.002) |
| NCT01775569 | Amlodipine | Phase 2 | 60 | PD | UPDRS motor | Ongoing; blood pressure effects noted |
| NCT04464100 | Isradipine | Phase 2 | 72 | PD | Safety, tolerability | Completed; favorable safety profile |
| Trial ID | Compound | Phase | Status | Indication | Notes |
|---|---|---|---|---|---|
| NCT05266114 | CK-206 | Phase 1 | Recruiting | Healthy volunteers | MCU inhibitor |
| NCT05391838 | AP-002 | Preclinical | IND-enabling | AD/PD | SOCE modulator |
| Trial ID | Intervention | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|---|---|---|---|---|---|---|
| NCT00940584 | Levetiracetam (Ca²⁺ modulator) | Phase 2 | 143 | MCI | Cognitive testing | Reduced hippocampal hyperactivity (p=0.03) |
| NCT02160041 | Levetiracetam | Phase 2 | 54 | AD | fMRI, cognition | Improved memory encoding (p=0.02) |
| NCT05035068 | Zonisamide (Ca²⁺) | Phase 2 | 90 | PD | UPDRS | Motor improvement observed (p=0.01) |
Calì T, et al. Calcium dysregulation in Alzheimer's disease: From molecular mechanisms to therapeutic opportunities. Cell Calcium. 2020. ↩︎
Moccia F, et al. Store-operated calcium entry in neurodegenerative diseases. Trends Neurosci. 2020. ↩︎
Zhou Q, et al. Calcium dysregulation in Parkinson's disease: Molecular mechanisms and therapeutic perspectives. CNS Neurosci Ther. 2017. ↩︎
Liu J, et al. Calcium dysregulation and excitotoxicity in amyotrophic lateral sclerosis. Neurobiol Aging. 2017. ↩︎
Qiu J, et al. MCU knock-down protects against excitotoxic cell death through mitochondrial calcium modulation. Proc Natl Acad Sci USA. 2014. ↩︎